Voretigene neparvovec-rzyl (Luxturna) for RPE65-associated retinal dystrophy
Customize your policy alerts
Sign up for Baylor Scott & White Health Plan Policy 249 alerts
Get alerted when Policy 249 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization for voretigene neparvovec-rzyl (Luxturna) for members with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It applies across lines of business unless otherwise specified, subject to the member’s benefit plan, applicable Medicare or Medicaid requirements, and federal or state mandates.
The 2026-08-27 policy history identifies minor formatting changes as the latest update.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.